Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 626 - 650 of 8154 in total
Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a...
Approved
Investigational
Matched Description: … It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties ... pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Description: … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. ... [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic ... Tirbanibulin blocks the molecular pathways that promote the proliferation, survival, and metastasis of
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and nonallergic forms of asthma where eosinophilia is prominent. ... cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of ... Elevated levels of eosinophils increase the risk for asthma exacerbations, including both allergic forms …
Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … Turoctocog alfa pegol is a pegylated version of [turoctocog alfa]. ... During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino ... from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of
Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952. It is spread primarily by the bite of infected mosquitos of the Aedes genus. Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia. Prior to...
Approved
Matched Description: … [A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus. ... [L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure ... Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in …
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … leukaemia (ALL), only after at least two other types of treatment have failed. ... Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. ... Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic …
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. ... formulation of CTLA4-Ig into clinical trials (RG2077). ... antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin …
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... linked to the Fc portion of immunoglobulin G1. ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial...
Approved
Matched Description: … treatment of facial spasmodic disorders in the early 1970s. ... The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the ... [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] …
Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Approved
Investigational
Matched Description: … Famciclovir is a prodrug of penciclovir with higher oral bioavailability. …
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Approved
Illicit
Investigational
Matched Description: … It has also been used in the symptomatic treatment of alcohol withdrawal. …
A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
Approved
Matched Description: … A corticosteroid used topically in the treatment of various skin disorders. …
In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational
Matched Description: … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin ... a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of
Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid...
Approved
Investigational
Matched Description: … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids ... In mice and nonhuman primate studies of animals with moderate and severe myelosuppression, in addition ... animal studies, oprelvekin was also shown to regulate intestinal epithelium growth by enhancing healing of
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within...
Approved
Investigational
Matched Description: … Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE. ... of bradykinin. ... The primary function of endogenous C1INH is to regulate the activation of the complement and contact …
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to...
Approved
Investigational
Matched Description: … Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily ... downstream modulation of both gonadotropin hormone and sex steroid levels. ... Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. ... On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal …
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in...
Approved
Investigational
Matched Description: … of extensive deformities or in the treatment of other forms of arthritis. ... Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold ... It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence …
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of...
Approved
Investigational
Matched Description: … migraine and the treatment of episodic cluster headache. ... Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of ... [A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile …
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including...
Approved
Matched Description: … of phentolamine. ... prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue ... anesthesia, and treatment of pharmacologically-induced mydriasis. …
Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of...
Approved
Vet approved
Matched Description: … The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of ... of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues ... The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating …
Displaying drugs 626 - 650 of 8154 in total